Skip to main content
VCbacked
Log inGet Started

Convergent Therapeutics

Cambridge, United States

Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.

$40.0M raised
Sep 2024
Series A
Health CareMedicalPharmaceutical

Top Investors

OrbiMedRA Capital ManagementNovo HoldingsInvus

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Convergent Therapeutics

How much funding has Convergent Therapeutics raised?
Convergent Therapeutics has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Who are Convergent Therapeutics's investors?
Convergent Therapeutics's investors include OrbiMed, RA Capital Management, Novo Holdings, Invus.
Where is Convergent Therapeutics headquartered?
Convergent Therapeutics is headquartered in Cambridge, United States.
What does Convergent Therapeutics do?
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
What stage is Convergent Therapeutics at?
Convergent Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Convergent Therapeutics — Funding & Investors." VCBacked, September 24, 2024, https://www.vcbacked.co/company/convergent-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2024). Convergent Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/convergent-therapeutics
Wikipedia (cite web)
{{cite web |title=Convergent Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/convergent-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Health Care

View all
Virtuoso Surgical
Nashville
Basata
Phoenix
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Sedivention
Munich$848K